Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple pill make CAR-T therapy work better for lymphoma?

NCT ID NCT05757219

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether giving the drug itacitinib before CAR-T cell therapy can improve outcomes for people with diffuse large B-cell lymphoma (DLBCL). The study will enroll 27 adults who are eligible for CAR-T treatment. Participants take itacitinib daily from after cell collection until 30 days after the CAR-T infusion, and researchers will track how long they stay cancer-free and whether severe side effects are reduced.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
itacitinib (a drug taken by mouth) and CAR-T cell therapy (a treatment that uses a patient's own immune cells to fight cancer)
What this could lead to
If successful, this combination could improve how long people with DLBCL stay cancer-free after CAR-T therapy, potentially doubling the current 6-month progression-free survival rate.
What could go wrong
This is a small, early-phase trial with only 27 participants, so results may not apply to everyone. Itacitinib may not improve outcomes and could add side effects like infections or organ issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33617, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.